isabelobrien, Author at European Medical Journal - Page 19 of 65

Stephen Chan

Onc Now: Episode 14: What Role Does Diet Play in Liver Cancer Prevention?

Stephen Chan, Clinical Professor at the Department of Clinical Oncology of the Chinese University of Hong Kong, shares new frontiers in liver cancer treatment.

Illustration of a heart with a monitor

Could gene therapy transform heart failure treatment?

A gene therapy for heart failure with preserved ejection fraction (HFpEF) has shown promising early results.

Boehringer Ingelheim's Christoph von der Goltz

Boehringer’s Christoph von der Goltz on setbacks and success in R&D

How can pharma navigate setbacks in drug development to deliver breakthroughs in R&D? Find out from Christoph von der Goltz, Boehringer.

Sanofi's chlamydia vaccine fast-tracked by FDA

This decision underscores the need for a preventative measure against the chlamydia, which affects millions worldwide.

Cartoon brain on green background

New study shines light on dementia in the workplace

A new study is challenging the belief that dementia is incompatible with modern work environments, with AI helping employees stay in work.

Rebecca Vermeulen, HBA STAR

HBA STAR Rebecca Vermeulen on purpose, passion and patient centricity

Rebecca Vermeulen, recipient of the HBA STAR award for 2025 joins the podcast to discuss what effective patient centricity looks like and more.

Jonathan Sackier, hema now highlights

Hema Now: Episode 13: Hema Now Highlights

Take look back at Jonathan Sackier’s highlights from the Hema Now podcast so far, exploring CAR-T therapies, bispecific antibodies and more.

Pharma’s trillion-dollar opportunity: Investing in women’s health

Women’s health remains chronically underfunded, yet closing the gap could unlock huge value for women and the global economy.

Pharma’s innovation ROI: Gains made, challenges ahead

The biopharmaceutical industry’s return on investment in innovation is increasing, but R&D costs are rising, according to a new Deloitte report.

British government buildings

VPAG hikes put UK life sciences at risk, warns pharma

The industry already contributes more than £17.6 billion directly to the UK economy, but it believes that growth has stagnated because of VPAG.